XS-04 for blood cancers that returned after treatment
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a new drug, XS-04, for people with certain blood cancers (like B-cell lymphoma, AML, or MDS) that have come back or not responded to standard treatments. The goal is to see if the drug is safe and can help shrink tumors or control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a type of B-cell lymphoma or myeloid cancer (like AML or MDS) that has come back or not improved after at least two previous treatments.
- You need to be in fairly good health (able to get out of bed and care for yourself).
- Your major organs (like heart, liver, kidneys, and bone marrow) must be working well enough based on blood tests.
- You cannot have serious heart, lung, or bleeding problems, or an active uncontrolled infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called FXS0683 to treat certain blood cancers (like lymphomas and leukemias) that haven't responded to standard treatments. Researchers want to find the right dose and see if it helps patients whose cancer has come back or isn't responding to other options.
This Phase 1 study tests BXCL701 in adults whose acute myeloid leukemia (AML) or high-blast myelodysplastic syndrome (MDS-EB-2) has come back or not responded to prior treatment. The goal is to find a safe dose and see how the treatment affects cancer cells.
This trial tests a new study drug, IKS03, for people with advanced B-cell non-Hodgkin lymphoma that has not responded to at least two prior treatments. The goal is to see if the drug is safe and how well it works.
This early-phase trial tests whether SYHX1903 is safe and tolerable in people whose blood cancers have come back or did not respond. It may help by finding a workable dose and early safety signals for patients who have limited options.
This study tests a new tablet called XNW5004 in patients with follicular lymphoma (a type of blood cancer) that has come back or stopped responding after multiple prior treatments. The goal is to see if this drug can help control the cancer in patients who have limited options.
This trial tests a new drug (AXT-1003) for people with advanced blood cancers (like non-Hodgkin lymphoma) or solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and how well it works.
Hear when a new Lymphoma, B-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.